New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; The lack of aspirin resistance among healthy individuals

Thrombosis Research

Volumn 131, Issue 4, 2013, Pages 320-324

  Kovács, Emese G ^a   Katona, Éva ^a   Bereczky, Zsuzsanna ^a   Homoródi, Nóra ^a   Balogh, László ^a   Tóth, Eszter ^a   Péterfy, Hajna ^b   Kiss, Róbert G ^c   Édes, István ^a   Muszbek, László ^a,d  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Diagnosticum Inc   (Hungary)

^c State Health Center   (Hungary)

^d UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

aspirin; aspirin resistance; cyclooxygenase; platelet; thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 1; MONOCLONAL ANTIBODY; NONAPEPTIDE; THROMBOXANE B2;

ACETYLATION; ADULT; AMINO ACID SEQUENCE; ARTICLE; FEMALE; HUMAN; IMMUNOASSAY; MALE; NORMAL HUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE RICH PLASMA; VOLUNTEER; WESTERN BLOTTING;

ACETYLATION; ADULT; ASPIRIN; BLOOD PLATELETS; CYCLOOXYGENASE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; YOUNG ADULT;

EID: 84875730184     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.01.033     Document Type: Article

References (27)

1. J.W. Eikelboom, J. Hirsh, F.A. Spencer, T.P. Baglin, and J.I. Weitz Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e89S e119S
2. C. Patrono, L.A. Garcia Rodriguez, R. Landolfi, and C. Baigent Low-dose aspirin for the prevention of atherothrombosis N Engl J Med 353 2005 2373 2383
3. A.T. Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
4. C. Baigent, L. Blackwell, R. Collins, J. Emberson, J. Godwin, and R. Peto Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
5. P.O. Vandvik, A.M. Lincoff, J.M. Gore, D.D. Gutterman, F.A. Sonnenberg, and P. Alonso-Coello Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e637S e668S
6. D.L. Simmons, R.M. Botting, and T. Hla Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition Pharmacol Rev 56 2004 387 437
7. R.J. Kulmacz, W.A. van der Donk, and A.L. Tsai Comparison of the properties of prostaglandin H synthase-1 and - 2 Prog Lipid Res 42 2003 377 404
8. C. Patrono, and B. Rocca Aspirin, 110 years later J Thromb Haemost 7 Suppl. 1 2009 258 261
9. J.M. Sweeny, D.A. Gorog, and V. Fuster Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements Nat Rev Cardiol 6 2009 273 282
10. D.A. Gorog, J.M. Sweeny, and V. Fuster Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact? Nat Rev Cardiol 6 2009 365 373
11. D. Varon, and G. Spectre Antiplatelet agents Hematology Am Soc Hematol Educ Program 2009 267 272
12. A. Papathanasiou, J. Goudevenos, and A.D. Tselepis Aspirin resistance in cardiovascular disease: pathogenesis, diagnosis and clinical impact Curr Pharm Des 15 2009 1085 1094
13. A.J. Farre, J. Tamargo, P.J. Mateos-Caceres, L. Azcona, and C. Macaya Old and new molecular mechanisms associated with platelet resistance to antithrombotics Pharm Res 27 2010 2365 2373
14. J.L. Mehta, and B. Mohandas Aspirin resistance: Fact or fiction? A point of view World J Cardiol 2 2010 280 288
15. R. Fitzgerald, and M. Pirmohamed Aspirin resistance: effect of clinical, biochemical and genetic factors Pharmacol Ther 130 2011 213 225
16. C. Stahli, T. Staehelin, V. Miggiano, J. Schmidt, and P. Haring High frequencies of antigen-specific hybridomas: dependence on immunization parameters and prediction by spleen cell analysis J Immunol Methods 32 1980 297 304
17. Z. Hevessy, G. Haramura, Z. Boda, M. Udvardy, and L. Muszbek Promotion of the crosslinking of fibrin and alpha 2-antiplasmin by platelets Thromb Haemost 75 1996 161 167
18. F. Santilli, B. Rocca, R. De Cristofaro, S. Lattanzio, L. Pietrangelo, and A. Habib Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin «resistance» J Am Coll Cardiol 53 2009 667 677
19. C. Patrono, G. Ciabattoni, E. Pinca, F. Pugliese, G. Castrucci, and A. De Salvo Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects Thromb Res 17 1980 317 327
20. G. Ciabattoni, J. Maclouf, F. Catella, G.A. FitzGerald, and C. Patrono Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine Biochim Biophys Acta 918 1987 293 297
21. P.M. Ho, J.A. Spertus, F.A. Masoudi, K.J. Reid, E.D. Peterson, and D.J. Magid Impact of medication therapy discontinuation on mortality after myocardial infarction Arch Intern Med 166 2006 1842 1847
22. K.A. Schwartz, D.E. Schwartz, K. Barber, M. Reeves, and A.C. De Franco Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients J Transl Med 6 2008 46
23. A.D. Michelson, M. Cattaneo, J.W. Eikelboom, P. Gurbel, K. Kottke-Marchant, and T.J. Kunicki Aspirin resistance: position paper of the Working Group on Aspirin Resistance J Thromb Haemost 3 2005 1309 1311
24. A.A. Weber, K.C. Zimmermann, J. Meyer-Kirchrath, and K. Schror Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance Lancet 353 1999 900
25. M.K. Halushka, and P.V. Halushka Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 105 2002 1620 1622
26. B. Rocca, P. Secchiero, G. Ciabattoni, F.O. Ranelletti, L. Catani, and L. Guidotti Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets Proc Natl Acad Sci U S A 99 2002 7634 7639
27. S. Riondino, E. Trifiro, L. Principessa, S. Mascioletti, L. Di Renzo, and C. Gaudio Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production Thromb Res 122 2008 359 365